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ABSTRACT
Aflibercept is a novel, recombinant, fusion
protein that consists of portions of vascular
endothelial growth factor (VEGF) receptor (R) 1
and VEGFR2 extracellular domains fused to the
Fc portion of human immunoglobulin G1. It
exhibits higher affinity for VEGF-A/-B and binds
all the VEGF isoforms (VEGF-B and -C, placental
growth factor). The efficacy of aflibercept was
assessed in two randomized, double-masked,
multicenter, active-controlled, clinical trials in
patients with choroidal neovascularization due
to exudative age-related macular degeneration
(AMD) and compared it’s efficacy to
ranibizumab, which is already Food and Drug
Administration (FDA)-approved for patients
with wet AMD. In the two trials known as
VIEW 1 and VIEW 2, aflibercept was as effective
when dosed as 2 mg every 8 weeks after 3
monthly loading doses compared to monthly
ranibizumab. Aflibercept was well tolerated
with very rare systemic adverse events,
including arterial thromboembolic events
(ATEs). The incidence of ATEs was 1.8% during
the first year of the clinical trials and included
non-fatal strokes, non-fatal myocardial
infarction, or death from vascular events or an
unknown cause. In November 2011, aflibercept
received FDA approval and is currently used in
clinical practice for patients with wet AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blindness among the elderly in
the developed world [1]. As the population ages,
AMD has become the most common cause of
vision loss [2]. In the United States (US), it
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affects more than 1.75 million people [3] and is
estimated to affect approximately 14 million
people worldwide. There are two forms of AMD:
the non-neovascular or dry form, which is the
most common, and the neovascular or wet
form. The wet form of AMD is responsible for
the majority of severe vision loss. Choroidal
neovascularization (CNV) is the hallmark of
neovascular AMD. CNV is characterized by
growth of abnormal blood vessels under the
macula with disruption of the blood retinal
barrier, bleeding, exudation, and eventually
scarring.
CNV has been classified into two forms:
classic and occult CNV. The classification
scheme was used in early AMD clinical trials.
In classic CNV, the lesions show a well-
demarcated appearance with early
hyperfluorescence that progressively leaks dye
to obscure it’s boundaries in late views of the
fluorescein angiogram. Occult CNV appears as
either late leakage from an undetermined
source at the level of the retinal pigment
epithelium (RPE) or as ill-defined early leakage
with less profuse leakage in late views as in
classic CNV. Patients can have 100% classic or
occult CNV, but many will have mixed forms of
CNV [4].
The pathogenesis of CNV in the setting of
AMD is poorly understood. However, there are
currently many reports suggesting that vascular
endothelial growth factor (VEGF) plays an
essential role [5–14]. Animal studies have
demonstrated that VEGF over expression in
the RPE leads to CNV [15, 16]. In mouse and
monkey models of laser-induced CNV,
intravitreal injections of an anti-VEGF-A
antibody prevented the development of CNV
and reduced leakage from pre-existing CNV
[17–20]. Since the establishment of VEGF as an
important factor in the development of neo-
vascularization, several drugs have been
developed to target this molecule [21] and
prevent the devastating consequences of
ocular neovascularization.
Ranibizumab and bevacizumab are both
VEGF inhibitors used for the treatment of AMD.
Ranibizumab is a recombinant, humanized,
affinity-matured, antibody fragment (Fab) that
neutralizes all active isoforms of VEGF-A, and
bevacizumab is a full-length, recombinant,
humanized, monoclonal antibody that binds
to and blocks the action of all isoforms of VEGF-
A [22]. Bevacizumab is used off-label for AMD as
it has only received Food and Drug
Administration (FDA) approval for the
treatment of cancer. Two pivotal phase 3
clinical trials, MARINA [23] and ANCHOR [24],
led to the FDA approval of ranibizumab. The
MARINA study looked at minimally classic and
occult CNV lesions comparing monthly
ranibizumab to sham injections while the
ANCHOR study evaluated monthly
ranibizumab injections versus sham injections
combined with verteporfin photodynamic
therapy (PDT) in predominantly classic CNV
due to AMD. The results were impressive and in
both trials 94% of treated patients lost less than
15 letters of best-corrected visual acuity (BCVA)
on the Early Treatment Diabetic Retinopathy
Study (ETDRS) chart at 12 and 24 months.
Although bevacizumab is used off-label
[25, 26], the clinical equivalence of monthly
bevacizumab and ranibizumab was recently
demonstrated in the National Eye Institute’s
Comparison of Age-Related Macular
Degeneration Treatment Trials (CATT) [27].
CATT was a 2-year, multicenter, randomized
clinical trial that showed monthly dosing of both
medications to be equivalent in terms of BCVA.
Patients treated with ranibizumab gained ?8.5
letters on the ETDRS chart whereas patients
treated with bevacizumab gained ?8.0 letters
after 1 year of monthly injections.
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METHODS
The authors reviewed medical literature using
PubMed and pertinent Internet postings
combined with analysis of key studies regarding
theuseofaflibercept for the treatmentofexudative
AMD. The main keywords used were aflibercept,
neovascular age-related macular degeneration,
ranibizumab, vascular endothelial growth factor,
wet age-related macular degeneration.
FUSION PROTEINS
Anti-VEGF monoclonal antibodies act via direct
interaction with binding domains on either
soluble VEGF ligands or membrane-bound
receptors. In contrast, fusion proteins act as
decoy receptors, binding with high affinity to
the VEGF-A ligand; thus, preventing binding and
subsequent activation of VEGF receptor (VEGFR)
1 and VEGFR2. The only VEGF fusion protein
currently in clinical use is aflibercept [28].
INTRODUCTION TO AFLIBERCEPT
Initially, four VEGF trap molecules were
constructed [29]. The parental VEGF Trap was
synthesized as a fusion protein combining the
constant region (Fc) of immunoglobulin G (IgG)1
with the first three domains of VEGFR1. It was
found to have very strong, picomolar-binding
affinity for the VEGF ligand. However, it had a
significant positive charge and as a consequence
bound nonspecifically to negatively charged
extracellular matrix proteins, resulting in short
systemic half-life (t). From the rest of the fusion
proteins, the modification that included the Fc
region of IgG1 fused with domain two of VEGFR1
and domain three of VEGFR2 was shown to have
high affinity for the VEGF-A ligand and less
positive charge. This modification increased the
tof theproteinandits invivoactivity.This fusion
protein is currently manufactured as aflibercept,
which exhibits higher affinity for VEGF-A/-B and
binds all the VEGF isoforms [VEGF-B and -C,
placental growth factor (PlGF)] (Fig. 1).
CHEMISTRY
AND PHARMACOKINETICS
Aflibercept is a soluble fusion protein. It has a
molecular weight of 115 kDa and is
manufactured from Chinese hamster ovary
cells that overexpress the fusion protein.
Aflibercept ophthalmic molecule is identical in
structure to the cancer drug, ziv-aflibercept;
however, it undergoes a different purification
process and the formulation contains different
buffer solutions that are less irritating when
injected intravitreally.
Fig. 1 Aﬂibercept mechanism of action. Aﬂibercept binds
to VEGF A-D and PIGF and prevents binding to the
receptors and further activation of the angiogenesis
cascade. ERK extracellular signal-regulated kinase, IgG1
immunoglobulin G1, PI3K phosphatidylinositol 3-kinase,
PIGF placental growth factor, MEK Mitogen-activated
protein/extracellular signal-regulated kinase kinase, mTOR
mammalian target of rapamycin, VEGF vascular endothelial
growth factor, VEGFR vascular endothelial growth factor
receptor
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The pharmacokinetic properties of
aflibercept were initially determined by
injecting VEGF TrapR1R2 (aflibercept 4 mg/kg)
subcutaneously into mice. The maximum
plasma concentration (Cmax) and area under
the concentration–time curve (AUC) were
16 lg/mL and 36.28 lg days/m, respectively.
Kd for the predominant VEGF isoform in
humans, VEGF165, was 0.5 pM [30].
Bioavailability following intravenous and
subcutaneous dosing was nearly identical [31].
Following intravitreal administration of
aflibercept (2 mg per eye), mean plasma Cmax
for free aflibercept was 0.02 lg/mL and was
attained in 1–3 days. The t of aflibercept
following intravitreal administration in
humans is unknown and the predicted t is
based on mathematical models [32, 33]. In
rabbits, the intravitreal t of aflibercept is 4.6
versus 3 days for ranibizumab (Table 1) [34].
Aflibercept did not accumulate in the plasma
when administered as repeated intravitreal
doses every 4 weeks. Pharmacokinetic studies
showed that the VEGF Trap molecule forms a
1:1 stable and inert complex with the VEGF-A
ligand [35].
CLINICAL EFFICACY AND SAFETY
Phase 1/2 Studies
In a phase 1, randomized, double-blind, placebo-
controlled trial in 25 patients with subfoveal CNV
from AMD, intravenous aflibercept (1.0 or 3.0 mg/
kg) achieved a dose-dependent decrease in retinal
thickness on optimal coherence tomography
(OCT). However, the study was discontinued due
to dose-dependent systemic toxicity, with one
patient developing hypertension and another
proteinuria [36]. The safety, tolerability, and
biological activity of intravitreal VEGF Trap-Eye
in the treatment of neovascular AMD were
evaluated in the Clinical Evaluation of Anti-
angiogenesis in the Retina-1 (CLEAR-IT-1) study
[37]. During this phase 1 study, 21 patients were
monitored for safety, changes in foveal thickness
on OCT, BCVA, and lesion size on fluorescein
angiography (FA) for 6 weeks. No adverse systemic
or ocular events were noted and visual acuity
remained stable or improved C3 lines in 95% of
patients with a mean increase in BCVA of 4.6
letters at 6 weeks [36]. Patients had a substantial
decrease in foveal thickness on OCT.
This was followed by the phase 2 CLEAR-IT 2
trial, a prospective, randomized, multicenter,
trial evaluating VEGF Trap-Eye at different doses
and dosing intervals. Patients (n = 157) were
randomized to five dose groups and treated with
VEGF Trap-Eye in one eye. Two groups received
monthly doses of either 0.5 or 2.0 mg for
12 weeks (at weeks 0, 4, 8, and 12) and three
groups received 3-monthly doses of 0.5, 2.0, or
4.0 mg for 12 weeks (at weeks 0 and 12).
Following this initial dosing period, patients
Table 1 Pharmacokinetic and pharmacodynamic
characteristics of aﬂibercept [34]
• Formulation: intravitreal injection
• Dose: 2 mg in 0.05 mL
• Dosing: every month for 3 months and then every
2 months
Pharmacokinetics
• Time to peak intraocular concentration: immediately
following dose
• Volume of distribution: 4 mL
• Half-life: 4.6 days
Pharmacodynamics
• Targets: VEGFA-D, PIGF
• Effect: prevents VEGF receptor activation and
stimulation of the angiogenesis cascade
PIGF placental growth factor, VEGF vascular endothelial
growth factor
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were treated with the same dose of VEGF Trap-
Eye on an as-required basis until week 52. After
12 weeks of treatment, there was a mean
decrease in central retinal thickness of 119 lm
from baseline in all groups. Improvements in
visual acuity and retinal thickness were greater
in the monthly dosing groups compared with
the 3-monthly dosing groups, showing a clear
benefit from initial monthly injections. Patients
initially dosed on a 2.0 mg monthly schedule
received an average of 1.6 more injections and
those initially dosed on a 0.5 mg monthly
schedule received an average of 2.5 injections.
The median time to first reinjection in all
groups was 129 days and 19% of patients
required no more injections at week 52.
Patients in the 2 monthly dosing groups also
exhibited mean decreases in retinal thickness of
143 lm in the 2.0 mg group (P\0.0001) and
125 lm in the 0.5 mg group (P\0.0001) at
52 weeks as measured by OCT [38, 39].
Phase 3
VIEW 1 and VIEW 2 (VEGF Trap-Eye:
Investigation of efficacy and safety in wet
AMD) were pivotal phase 3, double-masked,
randomized, multicenter studies comparing
aflibercept and ranibizumab in patients with
wet AMD. VIEW 1 enrolled 1,217 patients in the
US and Canada and VIEW 2 enrolled 1,240
patients in the European Union, Asia Pacific,
Japan, and Latin America. Both studies
evaluated the percentage of patients who
maintained visual acuity, defined as loss of
fewer than 15 letters of BCVA on the ETDRS
chart (3 lines) at 52 weeks. Patients were treated
with three different aflibercept dosing regimens,
0.5 mg every 4 weeks, 2 mg every 4 weeks, and
2 mg every 8 weeks (following 3 initial monthly
injections), compared to ranibizumab 0.5 mg
every 4 weeks. At 52 weeks, the VIEW 1 study
showed that in the aflibercept groups, vision
was maintained in 96% of patients receiving
0.5 mg monthly, 95% of patients receiving 2 mg
monthly, and 95% of patients receiving 2 mg
every 2 months, which was non-inferior and
clinically equivalent to the group receiving
ranibizumab 0.5 mg monthly, where 94% of
patients maintained vision [40]. VIEW 2 results
were almost identical. In the aflibercept groups,
vision was maintained in 96% of patients
receiving aflibercept 0.5 mg monthly, 96% of
patients receiving 2 mg monthly, and 96% of
Table 2 Phase 3 clinical trials of aﬂibercept in AMD [40]



















Number of patients n = 301 n = 304 n = 304 n = 306 n = 309 n = 291
Maintenance of VA % 94% 95% 94% 95% 95% 95%
Mean VA improvement
in letters by ETDRS
7.9 10.9 8.1 8.9 7.6 9.4
3-line improvement on
the ETDRS chart %
31% 38% 31% 31% 29% 34%
AMD age-related macular degeneration, ETDRS Early Treatment Diabetic Retinopathy Study, VA visual acuity, VIEW
Vascular endothelial Growth Factor (VEGF) Trap-Eye: Investigation of efﬁcacy and safety in wet age-related macular
degeneration
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patients receiving 2 mg every 2 months. In the
group receiving ranibizumab 0.5 mg monthly,
94% of patients maintained vision (Table 2)
[40]. Based on these phase 3 results, aflibercept
received FDA approval for the treatment of wet
AMD in November 2011. The approved dose
was 2 mg and the approved treatment regimen
was a loading dose of 3 monthly injections
followed by dosing every 8 weeks thereafter.
The 2-year results were recently announced by
Regeneron Pharmaceuticals, Inc. and showed
sustained improvement in visual acuity. During
the second year, patients received treatment on
an as-required basis, when met specific
treatment criteria, but at least one injection
every 12 weeks [40]. In an integrated analysis of
the VIEW 1 and VIEW 2 studies, the visual
acuity gain from baseline in the aflibercept 2 mg
every 8 weeks group at week 96 was ?7.6 letters
(versus ?8.4 letters at week 52), with an average
of 11.2 injections over 2 years and 4.2 injections
during the second year. The visual acuity gain
from baseline in the monthly ranibizumab
group at week 96 was ?7.9 letters (versus ?8.7
letters at week 52, with an average of 16.5
injections over 2 years and 4.7 injections during
the second year) [40]. Regarding the anatomical
results, all aflibercept groups achieved
reductions in central retinal thickness similar
to those for monthly ranibizumab as assessed by
OCT. Initially, there was a large and rapid
reduction in retinal thickness evident by week
4 that was maintained to week 52. Minor
fluctuations in central retinal thickness were
seen in the 2 mg every 2 months group after
sham injections in the VIEW 2 study. However,
these fluctuations attenuated over time [40].
Aflibercept was well tolerated with very rare
systemic adverse events, including arterial
thromboembolic events (ATEs). The incidence
of ATEs was 1.8% during the first year of the
clinical trials and included non-fatal strokes,
non-fatal myocardial infarction, or death from
vascular events or an unknown cause. When
compared to ranibizumab, differences were
noted in the pre-specified analyses of
intraocular pressure, with fewer aflibercept-
treated patients experiencing an increase in
intraocular pressure over the 52 weeks in the
VIEW 1 and VIEW 2 studies.
DISCUSSION
Anti-VEGF therapy has improved the quality
of life of patients with neovascular AMD.
Ranibizumab was the first medication to not
only preserve but also improve vision in
patients with wet AMD. The MARINA [23]
and ANCHOR [24, 41] trials established
ranibizumab as an effective therapy when
dosed monthly. It has been shown to
stabilize vision in 94% of patients and to
actually improve vision by 3 or more lines in
almost 40% of patients. The PIER [42] trials
showed that ranibizumab is less effective
when dosed quarterly or as needed. The
PRONTO study, a single investigator-
sponsored trial, showed that it is possible to
extend the time between as-needed injections
when patients are followed closely with
frequent examinations and OCT testing [43,
44]. On the other hand, there is a subcategory
of patients who show little if any response to
therapy with persistent or rebound increase in
macular fluid. Usually patients who receive
three consecutive injections of ranibizumab
without anatomical resolution of intraretinal
or subretinal fluid are defined as non-
responders. For these patients, biweekly
dosing of the medication is recommended
[45].
VEGF Trap-Eye differs from established anti-
VEGF therapies, having a higher binding
affinity for VEGF-A and VEGF-B as well as
94 Ophthalmol Ther (2013) 2:89–98
123
PIGF. Phase 1 data demonstrated acceptable
safety and tolerability of VEGF Trap-Eye in the
treatment of neovascular AMD. In phase 2
studies, patients dosed in a similar fashion to
ranibizumab demonstrated stabilization of their
vision at 1 year. Two phase 3 studies showed at
year 1 that aflibercept can be dosed every
2 months after three initial monthly injections
with equivalent results to monthly
ranibizumab. During the second year, the
number of as-required injections is less
compared to ranibizumab. Furthermore, a
recent retrospective study showed that
patients who do not respond to ranibizumab
have better visual and anatomical outcomes
when switched to aflibercept [46].
Currently, the main issue with anti-VEGF
therapy is the cost and the number of office
visits per patient [47]. At a cost of
approximately $2,000 per injection, the cost to
treat wet AMD patients in the US exceeds $10
billion per year. The CATT study showed that
bevacizumab, which costs $15–50 per injection,
has similar efficacy to ranibizumab when dosed
monthly. Due to the high cost, many
ophthalmologists have turned to bevacizumab
as the alternative intravitreal agent in the
treatment of wet AMD. On the other hand,
aflibercept is more expensive than
bevacizumab, but as effective as ranibizumab
when dosed bimonthly and offers the
advantage of less frequent injections. Every
intraocular injection poses a risk of infection
(1 in 4,000 to 1 in 8,000) and is uncomfortable
for the patient. The decision of which
medication to choose should be based on the
clinician’s judgment and the patient’s response
to treatment. Conducting another clinical trial
comparing all three medications would be an
option, but we would most likely fail to show a
clear difference since all medications appear
effective using their labeled dosing regimen.
Therefore, the clinician needs to decide which
medication to use based on each individual
circumstance. However, the cost of treatment,
insurance coverage, and frequency of injections
seem to alter therapy on an individual basis.
FUTURE PERSPECTIVE
Aflibercept is one of three effective medications
for the treatment of neovascular AMD. The true
impact of this drug is that it has a longer t and
higher binding affinity for VEGF-A; therefore, it
can reduce the number of intraocular injections
and office visits. This was the rational and the
benefit behind the development of this new
medication. However, neither of the available
medications causes complete regression of the
choroidal neovascular membrane, which is the
hallmark of the disease. Based on the natural
history of the disease, the abnormal capillaries
that constitute the membrane continue leaking
fluid until a scar is formed in the macula and
the patient becomes legally blind. The focus
over the next decade will be to identify new
targets that can prevent or reverse choroidal
revascularization. Also, it is of utmost
importance to develop even longer-acting
therapies. Slow-release implant formulations of
current medications (e.g., ranibizumab reservoirs)
are under investigation, but hold many technical
difficulties given the nature and the molecular
weight of the medications. Different drug
formulations that could be used and eye drops
are another solution to the problem of monthly
injections, but so far all the drugs that have been
tested have failed. Currently, there are many
drugs under investigation (e.g., platelet-derived
growth factor inhibitors) and the primary effect is
inhibition of angiogenesis. With so many new
effective agents against angiogenesis, we have an
obligation to continue translational and clinical
research to identify new treatments for AMD.
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